- Jul 2018
-
europepmc.org europepmc.org
-
On 2015 Apr 23, Christopher Southan commented:
This is a valuable commentary but overlooks the importance of, as an adjunct to improved general transparency, also openly declaring the molecular structures of new therapeutic agents used in these trials. This aspect is detailed in "Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates" http://www.ncbi.nlm.nih.gov/pubmed/23159359
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
europepmc.org europepmc.org
-
On 2015 Apr 23, Christopher Southan commented:
This is a valuable commentary but overlooks the importance of, as an adjunct to improved general transparency, also openly declaring the molecular structures of new therapeutic agents used in these trials. This aspect is detailed in "Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates" http://www.ncbi.nlm.nih.gov/pubmed/23159359
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-